Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial

Clinical Neurology and Neurosurgery

Volumn 112, Issue 9, 2010, Pages 781-784

  Sieb, Jörn Peter ^a   Köhler, Wolfgang ^b  

^a General Hospital   (Germany)

^b Hospital Hubertusburg   (Germany)

Author keywords

Autoimmune disorder; Muscarinergic side effects; Myasthenia gravis; Pyridostigmine bromide; Sustained release formulation; Therapy

Indexed keywords

PYRIDOSTIGMINE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH STATUS; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYASTHENIA GRAVIS; NAUSEA; QUALITY OF LIFE; SUSTAINED DRUG RELEASE; UNSPECIFIED SIDE EFFECT; URINARY URGENCY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DEMOGRAPHY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; PYRIDOSTIGMINE BROMIDE; QUALITY OF LIFE; YOUNG ADULT;

EID: 77957813878     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.06.018     Document Type: Article

References (11)

1. U.A. Besinger, K.V. Toyka, M. Hömberg, K. Heininger, R. Hohlfeld, and A. Fateh-Moghadam Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity Neurology 33 1983 1316 1321
2. U. Breyer-Pfaff, U. Maier, A.M. Brinkmann, and F. Schumm Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis Clin Pharmacol Ther 37 1985 495 501
3. S.L. Cohan, J.L.W. Pohlmann, J. Mikszewski, and D.S. O'Doherty The pharmacokinetics of pyridostigmine Neurology 26 1976 536 539
4. D.B. Drachman Therapy of myasthenia gravis 3rd series. A.G. Engel, Neuromuscular junction disorders. Handbook of clinical neurology vol. 91 2008 Elsevier Edinburgh 253 272
5. A. Jaretzki III, R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, and D.B. Sanders Myasthenia gravis: recommendations for clinical research standards Neurology 55 2000 16 23
6. H.S. Milner-Brown, M. Mellenthin, M.L. Sharma, and R.G. Miller Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis Neurology 37 1987 800 803
7. F. Schumm, H.J. Gaertner, G. Wiatr, and J. Dichgans Serumspiegel von Pyridostigmin bei Myasthenia gravis: Methoden und klinische Bedeutung Fortschr Neurol Psychiatr 53 1985 201 211
8. J.P. Sieb, and W. Köhler Retardiertes Pyridostigmin in der Myasthenie-Behandlung - Ergebnisse einer nicht-interventionellen Beobachtungsstudie Aktuel Neurol 36 2009 4 7
9. The EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group Health Policy 16 1990 199 208
10. M.C. White, P. De Silva, and C.W.H. Havard Plasma pyridostigmine levels in myasthenia gravis Neurology 31 1981 145 150
11. ®. Kurzübersicht zu Eigenschaften und Wirkungen 2000 Herbert Utz Verlag München